Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

BTMD vs AMWL vs HIMS vs DOCS

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
BTMD
biote Corp.

Medical - Care Facilities

HealthcareNASDAQ • US
Market Cap$96M
5Y Perf.-77.5%
AMWL
American Well Corporation

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$133M
5Y Perf.-96.8%
HIMS
Hims & Hers Health, Inc.

Medical - Equipment & Services

HealthcareNYSE • US
Market Cap$7.30B
5Y Perf.+159.6%
DOCS
Doximity, Inc.

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$5.23B
5Y Perf.-55.4%

BTMD vs AMWL vs HIMS vs DOCS — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
BTMD logoBTMD
AMWL logoAMWL
HIMS logoHIMS
DOCS logoDOCS
IndustryMedical - Care FacilitiesMedical - Healthcare Information ServicesMedical - Equipment & ServicesMedical - Healthcare Information Services
Market Cap$96M$133M$7.30B$5.23B
Revenue (TTM)$188M$182M$2.35B$638M
Net Income (TTM)$16M$-88M$128M$239M
Gross Margin70.1%38.7%69.7%89.7%
Operating Margin15.4%-50.6%4.6%37.4%
Forward P/E2.9x58.3x16.8x
Total Debt$110M$5M$1.12B$12M
Cash & Equiv.$24M$182M$229M$210M

BTMD vs AMWL vs HIMS vs DOCSLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

BTMD
AMWL
HIMS
DOCS
StockJun 21May 26Return
biote Corp. (BTMD)10022.5-77.5%
American Well Corpo… (AMWL)1003.2-96.8%
Hims & Hers Health,… (HIMS)100259.6+159.6%
Doximity, Inc. (DOCS)10044.6-55.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: BTMD vs AMWL vs HIMS vs DOCS

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: DOCS leads in 3 of 7 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. biote Corp. is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. AMWL and HIMS also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
BTMD
biote Corp.
The Value Play

BTMD is the #2 pick in this set and the best alternative if value and dividends is your priority.

  • Lower P/E (2.9x vs 16.8x)
  • 2.2% yield; the other 3 pay no meaningful dividend
Best for: value and dividends
AMWL
American Well Corporation
The Momentum Pick

AMWL is the clearest fit if your priority is momentum.

  • +14.5% vs DOCS's -56.2%
Best for: momentum
HIMS
Hims & Hers Health, Inc.
The Growth Play

HIMS is the clearest fit if your priority is growth exposure and long-term compounding.

  • Rev growth 59.0%, EPS growth -3.8%, 3Y rev CAGR 64.5%
  • 188.5% 10Y total return vs DOCS's -51.0%
  • 59.0% revenue growth vs BTMD's -2.5%
Best for: growth exposure and long-term compounding
DOCS
Doximity, Inc.
The Income Pick

DOCS carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.

  • beta 0.99
  • Lower volatility, beta 0.99, Low D/E 1.1%, current ratio 6.97x
  • Beta 0.99, current ratio 6.97x
  • 37.5% margin vs AMWL's -48.2%
Best for: income & stability and sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthHIMS logoHIMS59.0% revenue growth vs BTMD's -2.5%
ValueBTMD logoBTMDLower P/E (2.9x vs 16.8x)
Quality / MarginsDOCS logoDOCS37.5% margin vs AMWL's -48.2%
Stability / SafetyDOCS logoDOCSBeta 0.99 vs HIMS's 2.48, lower leverage
DividendsBTMD logoBTMD2.2% yield; the other 3 pay no meaningful dividend
Momentum (1Y)AMWL logoAMWL+14.5% vs DOCS's -56.2%
Efficiency (ROA)DOCS logoDOCS20.7% ROA vs AMWL's -25.1%, ROIC 20.0% vs -95.1%

BTMD vs AMWL vs HIMS vs DOCS — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

BTMDbiote Corp.
FY 2025
Product Revenue
78.2%$187M
Dietary Supplements
17.9%$43M
Service Revenue
2.2%$5M
Other Service Revenue
1.2%$3M
Training Service Revenue
0.5%$1M
AMWLAmerican Well Corporation
FY 2025
Platform Subscription
53.1%$132M
Visits
37.8%$94M
Others
9.1%$23M
HIMSHims & Hers Health, Inc.

Segment breakdown not available.

DOCSDoximity, Inc.
FY 2025
Subscription
95.3%$544M
Service, Other
4.7%$27M

BTMD vs AMWL vs HIMS vs DOCS — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLDOCSLAGGINGAMWL

Income & Cash Flow (Last 12 Months)

DOCS leads this category, winning 4 of 6 comparable metrics.

HIMS is the larger business by revenue, generating $2.3B annually — 12.9x AMWL's $182M. DOCS is the more profitable business, keeping 37.5% of every revenue dollar as net income compared to AMWL's -48.2%. On growth, HIMS holds the edge at +28.4% YoY revenue growth, suggesting stronger near-term business momentum.

MetricBTMD logoBTMDbiote Corp.AMWL logoAMWLAmerican Well Cor…HIMS logoHIMSHims & Hers Healt…DOCS logoDOCSDoximity, Inc.
RevenueTrailing 12 months$188M$182M$2.3B$638M
EBITDAEarnings before interest/tax$32M-$59M$164M$250M
Net IncomeAfter-tax profit$16M-$88M$128M$239M
Free Cash FlowCash after capex$29M-$42M$73M$314M
Gross MarginGross profit ÷ Revenue+70.1%+38.7%+69.7%+89.7%
Operating MarginEBIT ÷ Revenue+15.4%-50.6%+4.6%+37.4%
Net MarginNet income ÷ Revenue+8.3%-48.2%+5.5%+37.5%
FCF MarginFCF ÷ Revenue+15.2%-22.9%+3.1%+49.2%
Rev. Growth (YoY)Latest quarter vs prior year-8.3%-100.0%+28.4%+9.8%
EPS Growth (YoY)Latest quarter vs prior year-83.8%+44.5%-27.3%-16.2%
DOCS leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

BTMD leads this category, winning 3 of 6 comparable metrics.

At 2.9x trailing earnings, BTMD trades at a 95% valuation discount to HIMS's 55.4x P/E. On an enterprise value basis, BTMD's 4.6x EV/EBITDA is more attractive than HIMS's 46.5x.

MetricBTMD logoBTMDbiote Corp.AMWL logoAMWLAmerican Well Cor…HIMS logoHIMSHims & Hers Healt…DOCS logoDOCSDoximity, Inc.
Market CapShares × price$96M$133M$7.3B$5.2B
Enterprise ValueMkt cap + debt − cash$182M-$45M$8.2B$5.0B
Trailing P/EPrice ÷ TTM EPS2.95x-1.34x55.43x23.41x
Forward P/EPrice ÷ next-FY EPS est.58.29x16.80x
PEG RatioP/E ÷ EPS growth rate0.29x
EV / EBITDAEnterprise value multiple4.64x46.50x21.09x
Price / SalesMarket cap ÷ Revenue0.50x0.53x3.11x9.16x
Price / BookPrice ÷ Book value/share0.52x13.50x4.83x
Price / FCFMarket cap ÷ FCF3.19x98.70x19.60x
BTMD leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

DOCS leads this category, winning 5 of 9 comparable metrics.

DOCS delivers a 24.4% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-33 for AMWL. DOCS carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to HIMS's 2.07x. On the Piotroski fundamental quality scale (0–9), DOCS scores 9/9 vs HIMS's 4/9, reflecting strong financial health.

MetricBTMD logoBTMDbiote Corp.AMWL logoAMWLAmerican Well Cor…HIMS logoHIMSHims & Hers Healt…DOCS logoDOCSDoximity, Inc.
ROE (TTM)Return on equity-33.5%+23.7%+24.4%
ROA (TTM)Return on assets+15.1%-25.1%+6.0%+20.7%
ROICReturn on invested capital+11.3%-95.1%+10.7%+20.0%
ROCEReturn on capital employed+53.3%-36.6%+10.9%+22.3%
Piotroski ScoreFundamental quality 0–96649
Debt / EquityFinancial leverage0.02x2.07x0.01x
Net DebtTotal debt minus cash$86M-$178M$892M-$197M
Cash & Equiv.Liquid assets$24M$182M$229M$210M
Total DebtShort + long-term debt$110M$5M$1.1B$12M
Interest CoverageEBIT ÷ Interest expense3.02x-239.18x
DOCS leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

HIMS leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in HIMS five years ago would be worth $27,393 today (with dividends reinvested), compared to $312 for AMWL. Over the past 12 months, AMWL leads with a +14.5% total return vs DOCS's -56.2%. The 3-year compound annual growth rate (CAGR) favors HIMS at 33.6% vs AMWL's -41.7% — a key indicator of consistent wealth creation.

MetricBTMD logoBTMDbiote Corp.AMWL logoAMWLAmerican Well Cor…HIMS logoHIMSHims & Hers Healt…DOCS logoDOCSDoximity, Inc.
YTD ReturnYear-to-date-11.7%+64.3%-15.4%-40.0%
1-Year ReturnPast 12 months-41.7%+14.5%-45.0%-56.2%
3-Year ReturnCumulative with dividends-68.4%-80.2%+138.6%-24.3%
5-Year ReturnCumulative with dividends-78.2%-96.9%+173.9%-51.0%
10-Year ReturnCumulative with dividends-78.3%-98.3%+188.5%-51.0%
CAGR (3Y)Annualised 3-year return-31.9%-41.7%+33.6%-8.9%
HIMS leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — AMWL and DOCS each lead in 1 of 2 comparable metrics.

DOCS is the less volatile stock with a 0.99 beta — it tends to amplify market swings less than HIMS's 2.48 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AMWL currently trades 87.1% from its 52-week high vs DOCS's 34.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricBTMD logoBTMDbiote Corp.AMWL logoAMWLAmerican Well Cor…HIMS logoHIMSHims & Hers Healt…DOCS logoDOCSDoximity, Inc.
Beta (5Y)Sensitivity to S&P 5001.69x1.31x2.48x0.99x
52-Week HighHighest price in past year$4.75$9.15$70.43$76.51
52-Week LowLowest price in past year$1.27$3.71$13.74$20.55
% of 52W HighCurrent price vs 52-week peak+45.9%+87.1%+40.1%+34.0%
RSI (14)Momentum oscillator 0–10053.972.350.262.2
Avg Volume (50D)Average daily shares traded268K60K34.8M2.7M
Evenly matched — AMWL and DOCS each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: AMWL as "Hold", HIMS as "Hold", DOCS as "Buy". Consensus price targets imply 64.7% upside for DOCS (target: $43) vs -27.9% for AMWL (target: $6). BTMD is the only dividend payer here at 2.16% yield — a key consideration for income-focused portfolios.

MetricBTMD logoBTMDbiote Corp.AMWL logoAMWLAmerican Well Cor…HIMS logoHIMSHims & Hers Healt…DOCS logoDOCSDoximity, Inc.
Analyst RatingConsensus buy/hold/sellHoldHoldBuy
Price TargetConsensus 12-month target$5.75$26.20$42.79
# AnalystsCovering analysts151922
Dividend YieldAnnual dividend ÷ price+2.2%
Dividend StreakConsecutive years of raises0
Dividend / ShareAnnual DPS$0.05
Buyback YieldShare repurchases ÷ mkt cap+3.5%+0.0%+1.2%+2.3%
Insufficient data to determine a leader in this category.
Key Takeaway

DOCS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). BTMD leads in 1 (Valuation Metrics). 1 tied.

Best OverallDoximity, Inc. (DOCS)Leads 2 of 6 categories
Loading custom metrics...

BTMD vs AMWL vs HIMS vs DOCS: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is BTMD or AMWL or HIMS or DOCS a better buy right now?

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -2. 5% for biote Corp. (BTMD). biote Corp. (BTMD) offers the better valuation at 2. 9x trailing P/E, making it the more compelling value choice. Analysts rate Doximity, Inc. (DOCS) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — BTMD or AMWL or HIMS or DOCS?

On trailing P/E, biote Corp.

(BTMD) is the cheapest at 2. 9x versus Hims & Hers Health, Inc. at 55. 4x. On forward P/E, Doximity, Inc. is actually cheaper at 16. 8x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — BTMD or AMWL or HIMS or DOCS?

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +173. 9%, compared to -96. 9% for American Well Corporation (AMWL). Over 10 years, the gap is even starker: HIMS returned +188. 5% versus AMWL's -98. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — BTMD or AMWL or HIMS or DOCS?

By beta (market sensitivity over 5 years), Doximity, Inc.

(DOCS) is the lower-risk stock at 0. 99β versus Hims & Hers Health, Inc. 's 2. 48β — meaning HIMS is approximately 150% more volatile than DOCS relative to the S&P 500. On balance sheet safety, Doximity, Inc. (DOCS) carries a lower debt/equity ratio of 1% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — BTMD or AMWL or HIMS or DOCS?

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus -2. 5% for biote Corp. (BTMD). On earnings-per-share growth, the picture is similar: biote Corp. grew EPS 703. 5% year-over-year, compared to -3. 8% for Hims & Hers Health, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — BTMD or AMWL or HIMS or DOCS?

Doximity, Inc.

(DOCS) is the more profitable company, earning 39. 1% net margin versus -38. 4% for American Well Corporation — meaning it keeps 39. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOCS leads at 39. 9% versus -42. 2% for AMWL. At the gross margin level — before operating expenses — DOCS leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is BTMD or AMWL or HIMS or DOCS more undervalued right now?

On forward earnings alone, Doximity, Inc.

(DOCS) trades at 16. 8x forward P/E versus 58. 3x for Hims & Hers Health, Inc. — 41. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DOCS: 64. 7% to $42. 79.

08

Which pays a better dividend — BTMD or AMWL or HIMS or DOCS?

In this comparison, BTMD (2.

2% yield) pays a dividend. AMWL, HIMS, DOCS do not pay a meaningful dividend and should not be held primarily for income.

09

Is BTMD or AMWL or HIMS or DOCS better for a retirement portfolio?

For long-horizon retirement investors, Doximity, Inc.

(DOCS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 99)). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 48 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DOCS: -51. 0%, HIMS: +188. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between BTMD and AMWL and HIMS and DOCS?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BTMD is a small-cap deep-value stock; AMWL is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock; DOCS is a small-cap high-growth stock. BTMD pays a dividend while AMWL, HIMS, DOCS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

BTMD

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
  • Dividend Yield > 0.8%
Run This Screen
Stocks Like

AMWL

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 23%
Run This Screen
Stocks Like

HIMS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

DOCS

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 22%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform BTMD and AMWL and HIMS and DOCS on the metrics below

Revenue Growth>
%
(BTMD: -8.3% · AMWL: -100.0%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.